Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High – Still a Buy?

Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week high on Tuesday . The stock traded as high as $30.74 and last traded at $30.65, with a volume of 482730 shares changing hands. The stock had previously closed at $29.22.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Wells Fargo & Company upped their target price on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Bank of America assumed coverage on shares of Bicara Therapeutics in a report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Finally, Morgan Stanley upped their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $30.27.

Bicara Therapeutics Price Performance

The company’s 50 day simple moving average is $23.12 and its 200 day simple moving average is $19.95. The company has a market capitalization of $1.90 billion, a PE ratio of -10.43 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, equities analysts forecast that Bicara Therapeutics Inc. will post -3.48 EPS for the current year.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00. Following the transaction, the chief operating officer owned 191,641 shares of the company’s stock, valued at approximately $3,888,395.89. This trade represents a 6.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $20.42, for a total value of $187,864.00. Following the sale, the chief financial officer owned 145,355 shares in the company, valued at $2,968,149.10. This trade represents a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,900 shares of company stock valued at $1,420,704 in the last ninety days. 13.80% of the stock is currently owned by insiders.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently made changes to their positions in BCAX. Legal & General Group Plc lifted its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at $45,000. Larson Financial Group LLC increased its holdings in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.